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Abstract The human transferrin receptor (TfR) is proteolyti-
cally cleaved at R100 within the juxtamembrane stalk and to a
lesser extent at an alternative site. We examined the e¡ect of
stalk mutations on human TfR shedding in transfected CHO
cells. Point mutations at R100 led to an increase in alternative
shedding while the R100 cleavage product was undetectable.
Replacing the TfR-stalk by the corresponding sequences from
tumor necrosis factor-K or interleukin-6 receptor also led to
TfR ectodomain shedding. These results show that cleavage at
alternative sites can compensate for suppressed cleavage at the
major site and inhibitor studies reveal that at least three metal-
loproteases are involved in the shedding process.
* 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Many cell-surface proteins, including membrane-anchored
growth factors and precursors of cytokines, receptors, ectoen-
zymes, cell adhesion molecules and the Alzheimer precursor
protein, are proteolytically cleaved and release their ectodo-
mains into the extracellular space [1,2]. The ¢rst shedding
enzyme identi¢ed was the metalloprotease tumor necrosis fac-
tor-K (TNF-K) converting enzyme (TACE, ADAM-17) and
originally found to release TNF-K [3,4], but was later shown
to be involved in the shedding of a variety of other membrane
proteins (e.g. L-selectin, TNF receptors, transforming growth
factor-K (TGF-K)) [5]. Other important members of the same
protein family play an important role in ectodomain shedding,
including ADAM-9, ADAM-10 and ADAM-19 [6,7]. Besides
the ADAMs, other proteases are involved in shedding pro-
cesses, including matrix metalloproteinases (MMPs, e.g. stro-
melysin-1, matrilysin and MT4-MMP) [8^11] and serine pro-
teases (e.g. proteinase-3, neutrophil elastase and cathepsin G)
[12^14]. Ectodomain shedding is a widely branched network
of competitive processes, i.e. one type of protein can be
cleaved by di¡erent proteases or, vice versa, one protease
can cleave several di¡erent proteins.
Although to date many shedding enzymes, substrates and
cleavage sites have been identi¢ed, the mechanism of substrate
recognition and cleavage regulation remains an enigma. The
targets of shedding are type I and type II transmembrane
proteins as well as glycosylphosphatidylinositol-anchored pro-
teins [2]. Systematic mutational analyses of the cleavage sites
by deletion mutants and complete exchange of cleavage sites
between di¡erent proteins reveal no perceptible general rules
for consensus sequences or target motifs, suggesting that ter-
tiary structural features rather than sequence data are respon-
sible for recognition [15^17].
Besides proTNF-K one of the most important type II trans-
membrane proteins that is subject to shedding is the human
transferrin receptor (TfR). The TfR is a disul¢de-linked ho-
modimer (Cys-89 and Cys-98) [18] possessing a juxtamem-
brane stalk of 2.9 nm (amino acids 89^126) [19] that contains
an O-glycan at Thr-104 [20,21]. Shedding of the TfR occurs
C-terminally of Arg-100 [22] and is mediated by an integral
membrane metalloprotease sensitive to TAPI-2 (TNF-K pro-
tease inhibitor 2) [23]. Recently we have identi¢ed alternative
cleavage sites at Val-108 and Lys-95 within the TfR-stalk,
which are processed by neutrophil elastase and cathepsin G,
respectively [14]. A further cleavage site at Gly-91 was re-
ported for two truncated mutants of TfR [24].
In the present study we mutated amino acids in the TfR
around the major and alternative cleavage sites and replaced
the stalk by the corresponding segment from either the type II
membrane protein TNF-K or the type I membrane protein IL-
6R (interleukin-6 receptor). Using transfected CHO cells or
membrane preparations thereof we showed that all mutants
are substrates for one or several shedding proteases. The
amount and the molecular mass of the soluble products, how-
ever, as well as the inhibitor pattern di¡er from mutant to
mutant, indicating that di¡erent proteases are involved and
can compensate for each other.
2. Materials and methods
2.1. Materials
Monoclonal mouse antibody OKT9 was prepared as previously
described [25]. Other reagents: polyclonal anti-biotin antibody from
goat (Sigma, St. Louis, MO, USA); secondary antibodies (Dako A/S,
Glostrup, Denmark); blasticidin S, MMP inhibitor 1 and 2, TAPI-2,
recombinant human tissue inhibitor of metalloproteinases TIMP-3
(Calbiochem, Schwalbach, Germany); FCI (decanoyl-Arg-Val-Lys-
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Arg-chloromethylketone), human TIMP-1 and -2 (Alexis Biochemi-
cals, Gru«nberg, Germany); pefablocSC (Boehringer Mannheim,
Mannheim, Germany); FuGENE 6 (Roche, Basel, Switzerland); Dul-
becco’s phosphate-bu¡ered saline (PBS; Invitrogen, Karlsruhe, Ger-
many); EZ-Link sulfo-NHS-LC-biotin (Pierce, Rockford, IL, USA).
Other materials were purchased from Sigma.
2.2. Construction of TfR-stalk mutants
The TfR-cDNA was cloned from pGEM1-TR (kindly provided by
Marino Zerial, Max Planck Institute of Molecular Cell Biology and
Genetics, Dresden, Germany) into AgeI-de¢cient pcDNA6/V5-His B
(Invitrogen). Unique Bsu36I and AgeI restriction sites (corresponding
to amino acids K95 and P107, respectively) were introduced into the
stalk. The R100 and L101 mutations, as well as replacement of the
TfR-stalk (segment T96 to S106) by the corresponding TNF-K (71-
SPLAQAVRSSSR-82) and IL-6R (352-TSLPVQDSSSVP-363) stalk
(mutants referred to as TfR-TK and TfR-IR) were introduced by
ligation of synthetic dimeric oligonucleotides. The mutations V108G
and R109G were introduced into a TfR-segment (up to base pair 431)
by ligation of synthetic oligonucleotides using the AgeI and natural
PstI restriction sites. The segment was cloned into pcDNA6 contain-
ing full length TfR via XhoI/BtrI.
2.3. Transfection of CHO-TRVb cells and selection
CHO-TRVb cells (designated hereafter as TRVb; cells were kindly
provided by Timothy E. McGraw, Cornell University, New York,
USA), a cell line that does not express functional transferrin receptor
at their cell surface, were cultured at a 5% CO2 atmosphere and 37‡C
in Dulbecco’s modi¢ed Eagle’s medium with Glutamax supplemented
with penicillin/streptomycin and 5% fetal calf serum. Transfection was
performed with FuGENE 6 according to the manufacturer’s instruc-
tions and cells selected in the presence of blasticidin S.
2.4. Detection of soluble TfR (sTfR) from cell culture medium
For sTfR collection, 1U106 transfected TRVb cells were seeded on
uncoated 150 mm dishes and cultured for 4 days (¢nal cell number
3U107) in 30 ml medium. The cells were used for membrane prepa-
ration (see Section 2.5), the medium was centrifuged (500Ug, 4‡C, 10
min) to remove cellular debris and incubated overnight with 20 Wl
ferri-transferrin^Sepharose (prepared as described in [26]). The Seph-
arose was washed three times with PBS (150 mM NaCl, 10 mM
phosphate, pH 7.5) containing 1% Triton X-100, once with PBS
and boiled for 5 min with two-fold concentrated sodium dodecyl sul-
fate (SDS) sample bu¡er. The samples were separated on a 7.5%
polyacrylamide gel and TfR was detected by Western blotting using
OKT9 directed against the extracellular domain.
2.5. Detection of sTfR release from membranes
After removal of the medium the TRVb cells were placed on ice,
washed twice with 30 ml Dulbecco’s PBS and then incubated for 15
min with 1 ml 1:10 diluted Dulbecco’s PBS. After detaching the cells
from the dish, they were homogenized by douncing 30 times and
di¡erentially centrifuged at 500Ug for 15 min, followed by 2600Ug
for 15 min and ¢nally at 100 000Ug for 45 min. The membrane pellet
was washed once in 1 ml PBS and centrifuged at 20 000Ug for 20
min. The membrane pellet was resuspended in PBS to a ¢nal concen-
tration of 6 mg/ml and 30-Wl aliquots were incubated at 4‡C or 37‡C
for 18 h or stored at 320‡C. The samples were then centrifuged at
20 000Ug for 20 min at 4‡C and the supernatants analyzed by SDS
gel electrophoresis and Western blotting as described above.
2.6. Inhibition experiments
For inhibition experiments the membranes were incubated in the
presence of various inhibitors at the following ¢nal concentrations:
pefablocSC 1 mM, elastatinal 0.2 mM, 1,10-phenanthroline 3 mM,
MMP inhibitors 0.5 mM, TAPI-2 0.5 mM, TIMPs 0.5 WM, FCI 1 mM
and phosphoramidon 0.82 mM.
2.7. Detection of biotinylated cell surface TfR
Cell surface proteins of CHO cells were labeled with sulfo-NHS-
LC-biotin as described by Volz et al. [27]. After biotinylation, 3U107
cells were cultured for 24 h. sTfR was precipitated by ferri-transfer-
rin^Sepharose as described in Section 2.4, separated by SDS^PAGE
and detected by Western blotting using an anti-biotin antibody. Sub-
sequently the blot membrane was stripped of bound antibody by
incubating at 50‡C for 30 min in stripping bu¡er (62 mM Tris^HCl,
pH 6.7, 2% SDS (w/v) and 100 mM L-mercaptoethanol), and probed
with OKT9.
3. Results
3.1. Shedding of TfR mutants from cells and cell membranes
In HL-60 cells TfR is cleaved at the major cleavage site
Arg-100, but a second cleavage product of the same apparent
molecular mass as the alternative Val-108 product released by
neutrophil elastase in U937 cells could also be detected
[14,23]. To better characterize the shedding process we trans-
fected TRVb cells with human wild-type TfR (wt-TfR), TfR
point mutants (R100E, R100G, L101D, L101G, V108G,
R109G) and TfR where the stalk was replaced by either the
TNF-K-stalk or the IL-6R-stalk.
Untransfected TRVb cells did not express any detectable
TfR (data not shown). The TRVb cells transfected with wt-
TfR released mainly the major sTfR and a minor product of
lower molecular mass (Fig. 1A, lane 2), as shown for HL-60
cells [23]. Since the O-glycosylation at Thr-104 contributes to
a gel shift the di¡erent cleavage sites can be clearly distin-
guished. In contrast to wt-TfR, transfected cells expressing
the R100E or R100G mutant released mainly the alternative
product, indicating that suppression of cleavage at the major
site can be compensated by cleavage at the alternative site
(Fig. 1A, lanes 3 and 4). Unlike the R100 mutants, expression
of L101D and L101G led to release of the major sTfR (Fig.
1A, lanes 5 and 6). Furthermore, the amount of released sTfR
was dramatically increased (not recognizable in Fig. 1 since a
sample of the same dilution as used for R100 mutants would
strongly overload the gel) in comparison to wt-TfR whereas
expression of the R100 mutants did not signi¢cantly alter the
total amount of released sTfR. The V108G and R109G mu-
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Fig. 1. Anti-TfR Western blots showing the shedding of di¡erent
TfR mutants from transfected cells and cell membranes. A: sTfR
was precipitated from the supernatant of transfected TRVb cells by
ferri-transferrin^Sepharose. Lane 1 shows sTfR from untransfected
cells, lane 2 from wt-TfR, all other lanes from the mutants indi-
cated. B: sTfR from the supernatant of incubated TRVb mem-
branes. Lane 1 shows sTfR from untransfected cells, lanes 2 and 3
from wt-TfR incubated either at 4 or 37‡C, all other lanes from the
mutants indicated (incubation at 37‡C).
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tations at the alternative TfR-cleavage site processed by neu-
trophil elastase neither altered the ratio between major and
alternative sTfR nor the total amount of cleavage, even
though in some preparations the amount of the alternative
product appeared to be slightly reduced (Fig. 1A, lanes 7
and 8). TfR-TK was shed to a high degree from the cells
(not recognizable for the same reason stated above) and a
single product of a molecular mass between that of the major
TfR and the alternative TfR was released (Fig. 1A, lane 9).
Since it is unclear whether the TNF-K-stalk is O-glycosylated
in the present context the apparent molecular mass did not
allow a direct comparison to the cleavage site of wt-TfR. In
contrast to TfR-TK, two shedding products were released
from TfR-IR exhibiting the same molecular mass as observed
for wt-TfR (Fig. 1A, lane 10). The total amount of sTfR
released was similar to that of wt-TfR; however, the ratio
was shifted to the lower molecular mass product.
Studies performed recently with membrane preparations of
HL-60 cells revealed that the di¡erent sTfR products and their
amounts released are identical to those of whole cells [23].
Advantageously, for inhibitor studies (see Sections 3.2 and
3.3) the membrane assay is not a¡ected by the cytotoxicity
of inhibitors and guarantees an increased accessibility to the
enzyme. Therefore, we compared also for transfected TRVb
cells the results obtained for whole cells with those from the
membrane assay (method, see Section 2.5). Fig. 1B shows that
the shedding of wt-TfR and of R100E, R100G, V108G,
R109G, TfR-TK and TfR-IR is identical to that of living cells.
In contrast, the results for the L101 mutants di¡er from those
of living cells. L101D almost only released the alternative
product in the membrane assay and L101G released both
products (see Section 4).
3.2. Inhibitor pattern for the shedding of TfR point mutants
To further characterize sTfR release from membranes of
transfected TRVb cells we tested several protease inhibitors
using wt-TfR (cleaved predominantly at the major site) and
the R100G mutant (cleaved exclusively at the alternative site).
Since in U937 cells neutrophil elastase is responsible for alter-
native TfR-cleavage [14] we ¢rst tested elastatinal; however, it
had neither an e¡ect on the major nor the alternative sTfR
product (Fig. 2, lane 13). Unlike elastatinal the general metal-
loprotease inhibitor 1,10-phenanthroline blocked the release
of both shedding products (Fig. 2, lane 6). Testing more spe-
ci¢c inhibitors for MMPs and several ADAMs we showed
that both shedding processes are inhibited by MMP inhibitor
2, TAPI-2 and TIMP-1 (by the latter only weakly for the
alternative product) but not by TIMP-3 (Fig. 2). Interestingly,
TIMP-2 weakly inhibited only the release of the major sTfR
whereas MMP inhibitor 1 solely reduced the release of the
alternative product. The observation that the furin inhibitor
FCI also blocked sTfR release supports the assumption that
ADAMs are involved in TfR shedding since ADAMs are
activated by furin or furin-like proteases. The observed inhi-
bition by high concentrations of pefablocSC can be attributed
to the same mechanism [28]. Low concentrations of pefa-
blocSC had no e¡ect (data not shown). The results were con-
¢rmed when the sTfR bands from the R100G mutant treated
with various inhibitors were compared with the corresponding
lower band from the wt-TfR.
3.3. Inhibitor pattern for the shedding of TfR mutants with
completely altered stalk
The release of the lower molecular mass sTfR is predom-
inant in TfR-IR in the absence of inhibitor, thus the relative
intensity compared to the untreated control (Fig. 3, lane 2)
must be used for the comparison with wt-TfR and not the
absolute. Taking this into consideration the general inhibitor
pattern for the shedding of TfR-IR is very similar to wt-TfR
(Fig. 3, upper panel). TIMP-1 and TIMP-2 fully blocked the
cleavage of the major sTfR in TfR-IR; this may be due to the
already reduced levels. In contrast, TIMP-1, TIMP-2 and
MMP inhibitor 1 had no e¡ect on TfR-TK ectodomain re-
lease. Thus, the protease acting on TfR-TK di¡ers from those
generating the major and alternative sTfR from wt-TfR.
3.4. Localization of the shedding process
To determine the localization of the observed shedding pro-
cesses the surface proteins of the transfected CHO cells were
biotinylated and after 24 h TfR was precipitated from cell
lysates and cell culture supernatants. Supernatant from non-
biotinylated cells served as control. Biotinylated sTfR was
detected in the culture medium of all mutants examined
(Fig. 4). These results supply evidence that wt-TfR and all
mutants have to be directed to the cell surface before the
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Fig. 2. Anti-TfR Western blots showing the inhibition of sTfR re-
lease from cell membranes containing either wt-TfR (upper panel)
or the R100G mutant (lower panel). sTfR was detected in the
supernatant of TRVb membranes. Lanes 1 and 2 show the sTfR
after incubation at 320‡C and 37‡C without inhibitor, all other
lanes after incubation at 37‡C with the inhibitors indicated (concen-
trations, see Section 2.6). Lane 14 served as a control since TIMP-3
is delivered in 50% glycerin.
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release of sTfR can occur. It is conspicuous that the biotinyl-
ated TfR-TK is completely converted to the soluble form with-
in 24 h. The corresponding band in the OKT9 blot shows
newly synthesized TfR or TfR that was in the recycling path-
way during biotinylation. Thus the turnover of TfR-TK is
strongly enhanced in comparison to the wt-TfR and the other
mutants.
4. Discussion
For the majority of proteins released by shedding, neither
the protease(s) responsible nor the mechanism of regulation
has been identi¢ed yet [2]. To contribute to a better compre-
hension of the complex network of shedding proteases we
have, in the present study, systematically mutated the cleavage
site of a type II transmembrane protein underlying shedding,
the human TfR.
In transfected TRVb cells release of the major and alterna-
tive sTfR can be blocked by general inhibitors of metallopro-
teases but not by elastatinal. This suggests that neutrophil
elastase that is responsible for TfR-cleavage at an alternative
site in U937 cells [14] is not involved in the release of sTfR
from TRVb cells. This is probably due to large quantities of
neutrophil elastase in U937 cells [29] as compared to CHO
cells. Although the inhibitor pattern for major and alternative
cleavage was very similar, TIMP-2 inhibited cleavage only at
the major site and MMP inhibitor 1 solely at the alternative
site, indicating that two distinct metalloproteases are involved.
The inhibition by TIMP-1, TIMP-2, TAPI-2 and FCI in the
present work supports the suggestion that a member of the
ADAMs is responsible for TfR cleavage at the major site in
HL-60 cells [23].
Mutations in the TfR around the major cleavage site shifted
the product ratio from the major to the alternative sTfR. This
shows that the amino acids Arg-Leu in the P1 and P1P posi-
tion are important for correct processing and that single point
mutations can markedly a¡ect shedding. This is in accordance
with the observation that a point mutation in the juxtamem-
brane stalk of human angiotensin I-converting enzyme in-
voked the action of a distinct secretase [30]. Moreover, even
di¡erent stimuli can also contribute to the activation of dis-
tinct shedding activities [31]. For the TfR, the two disul¢de
bridges within the stalk may also play a role in receptor shed-
ding.
The observation that L101 mutations lead to intensive shed-
ding in cells but not in the membrane assay may be ascribed
to a di¡erent accessibility of these mutants for the involved
shedding protease(s). This is not due to a di¡erent subcellular
localization, since all mutants show biotinylated sTfR in the
cell culture supernatant. Thus, the TfR has to appear at the
cell surface before it is subject to shedding, indicating that the
biosynthetic pathway, which has been observed to be the lo-
cation of cleavage for another TfR mutant [24], can be ex-
cluded for the main and the alternative TfR-shedding pro-
tease.
The exchange of the TfR-stalk for the corresponding se-
quences from proTNF-K and IL-6R showed that cleavage of
the TfR does not depend on a unique structure of the stalk
since both mutants are subject to shedding. This is supported
by the low sequence homology in the stalk region between the
TfR of di¡erent species [19]. Whereas TfR-IR revealed a very
similar cleavage and inhibitor pattern as compared to wt-TfR,
TfR-TK substantially di¡ered from both. This is in so far
surprising as proTNF-K is, as TfR, a type II transmembrane
protein whereas the IL-6R is type I. However, previous stud-
ies have shown that replacement of the stalk in TNF-K by the
IL-6R-stalk in either orientation leads to resistance to shed-
ding, whereas IL-6R-mutants containing the TNF-K-stalk (in
either orientation) are subject to shedding [15], indicating that
the orientation is not the crucial point.
A set of mutations within the stalk of L-selectin did not
reveal any recognizable systematic dependence between pri-
mary structure and cleavability [32]. Insertion of the L-selectin
stalk into an unrelated unshed protein (B7.2) led to constitu-
tive non-inducible shedding and insertion of both the L-selec-
tin stalk and EGF domain led to constitutive and phorbol
ester-inducible shedding [17]. Remarkably, interchange of
the juxtamembrane sequences of two proteins that are not
subject to shedding led to a construct exhibiting phorbol es-
ter-inducible cleavage [16]. In summary, all results show that
it is predominantly the overall structure that appears to de-
termine where the protein is cleaved and how cleavage is
regulated.
In the present study, we show that suppression of TfR
cleavage evoked by mutations exclusively pertaining to the
TfR-stalk can be compensated by alternative shedding. In
the case of these mutations, inhibitor studies reveal that at
least three di¡erent metalloproteases are involved in the shed-
ding process.
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